Anti-Müllerian Hormone and Embryo Aneuploidy

Completed

• Conditions: Aneuploidy; Infertility

• Registration Number: NCT05723016
• Lead Sponsor: Clinica de la Mujer Medicina Reproductiva, Chile

Brief Summary

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels.

Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31
• Status Verified: 2023-02
• Study First Submitted: 2023-02-01
• Study First Submitted QC: 2023-02-01
• Last Update Submitted: 2023-02-01
• Study First Posted: 2023-02-10
• Last Update Posted: 2023-02-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.

Exclusion Criteria

• Data from oocyte donation cycles

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aneuplody rate	4 years

Secondary Outcome Measures

Name	Time	Method
Miscarriage rate	4 years
Clinical pregnancy rate	4 years

Trial Locations

Locations (1)

Clinica de la Mujer Medicina Reproductiva; 🇨🇱 Viña Del Mar, Valparaíso, Chile